1,419
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with Enbrel vs Etanar – Preliminary report

&
Pages 103-108 | Received 09 Jan 2017, Accepted 06 Apr 2017, Published online: 21 Apr 2017

References

  • Aarden L, Ruuls S, Wolbink G. 2008. Immunogenicity of anti-tumor necrosis factor antibodies: Toward improved methods of anti-antibody measurement. Curr Opin Immunol. 20:431–435.
  • Anderson P. 2005. Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles. Sem Arthritis Rheum. 34:19–22.
  • Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, Healey L, Kaplan S, Liang M, Luthra H, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumat. 31:315–324.
  • Atzeni F, Talotta R, Salaffi F, Cassinotti A, Varisco V, Battellino M, Ardizzone S, Pace F, Sarzi-Puttini P. 2013. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 12:703–708.
  • Bathon J, Martin R, Fleischmann R, Tesser J, Schiff M, Keystone E, Genovese M, Wasko M, Moreland L, Weaver A, et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 343:1586–1593.
  • Descotes J. 2009. Immunotoxicity of monoclonal antibodies. MAbs. 1:104–111.
  • Dore R, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P. 2007. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 25:40–46.
  • Emi Aikawa N, de Carvalho J, Artur Almeida Silva C, Bonfá E. 2010. Immunogenicity of anti-TNF-α agents in autoimmune diseases. Clin Rev Allergy Immunol. 38:82–89.
  • Garces S, Demengeot J, Benito-Garcia E. 2013. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann Rheum Dis. 72:1947–1955.
  • Geiler J, Buch M, McDermott M. 2011. Anti-TNF treatment in rheumatoid arthritis. Curr Pharm Des. 17:3141–3154.
  • Hoshino M, Yoshio T, Onishi S, Minota S. 2012. Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Modern Rheumatol. 22:532–540.
  • Jamnitski A, Krieckaert C, Nurmohamed M, Hart M, Dijkmans B, Aarden L, Voskuyl A, Wolbink G. 2012. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis. 71:88–91.
  • Kelley B. 2009. Industrialization of mAb production technology: The bioprocessing industry at a crossroads. MAbs. 1:443–452.
  • Keystone E, Schiff M, Kremer J, Kafka S, Lovy M, DeVries T, Burge D. 2004. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multi-center, randomized, double-blind, placebo-controlled trial. Arthritis Rheumat. 50:353–363.
  • Klareskog L, Gaubitz M, Rodríguez-Valverde V, Malaise M, Dougados M, Wajdula J. 2011. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol. 29:238–247.
  • Klareskog L, van der Heijde D, de Jager J, Gough A, Kalden J, Mola E, Martín Mola E, Pavelka K, Sany J, Settas L, et al. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet. 363:675–681.
  • Moreland L, Schiff M, Baumgartner S, Tindall E, Fleischmann R, Bulpitt K, Weaver A, Keystone E, Furst D, Mease P, et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 130:478–486.
  • Roger S. 2010. Biosimilars: Current status and future directions. Expert Opin Biol Ther. 10:1011–1018.
  • Rondon F. 2010. Etanar therapy in real-life patients with rheumatoid arthritis [abstract]. Arthritis Rheumat. 62(Suppl 10):1811.
  • Santos-Moreno P. 2015. Clinical outcomes in a cohort of Colombian patients with rheumatoid arthritis treated with Etanar, a new biologic type rhTNFR:Fc. Clin Exp Rheumatol. 33:858–862.
  • Santos-Moreno P. 2016. Direct comparative effectiveness among 3 anti-tumor necrosis factor biologics in a real-life cohort of patients With rheumatoid arthritis. J Clin Rheumatol. 22:57–62.
  • Shukla A, Thömmes J. 2010. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 28:253–261.
  • Singh J, Christensen R, Wells G, Suarez-Almazor M, Buchbinder R, Lopez-Olivo M, Ghogomu E, Tugwell P. 2009. Biologics for rheumatoid arthritis: An overview of Cochrane reviews. Cochrane Database Syst Rev. 4:CD007848.
  • van der Laan J, van Loveren H. 2005. Current status and burning issues in immunotoxicity testing of drugs. Toxicol Appl Pharmacol. 207:435–440.
  • Venables W, Ripley B, editors. 2002. Modern applied statistics with issues of accuracy and scale. New York: Springer.
  • Vincent F, Morand E, Murphy K, Mackay F, Mariette X, Marcelli C. 2013. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective. Ann Rheum Dis. 72:165–178.
  • Weinblatt M, Kremer J, Bankhurst A, Bulpitt K, Fleischmann R, Fox R, Jackson C, Lange M, Burge D. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 340:253–259.